Stocks and Investing
Stocks and Investing
Thu, May 11, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Geulah Livshits Maintained (SNTI) at Strong Buy with Decreased Target to $60 on, May 11th, 2023
Geulah Livshits of Chardan Capital, Maintained "Senti Biosciences, Inc." (SNTI) at Strong Buy with Decreased Target from $70 to $60 on, May 11th, 2023.
Geulah has made no other calls on SNTI in the last 4 months.
There is 1 other peer that has a rating on SNTI. Out of the 1 peers that are also analyzing SNTI, all agrees with Geulah's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $20 on, Friday, March 24th, 2023
Contributing Sources